Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMPACT1 open-label extension of TACTT2
2013-005588-24Phase 3Completed
- Sponsor
- Altamira Therapeutics
- Start
- Mar 2014
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Keyzilen in tinnitus, sponsored by Altamira Therapeutics. Primary endpoint: Occurrence of clinically relevant hearing threshold deterioration after each treatment cycle. Started Mar 2014; status: completed.
02
Drugs
Keyzilen
03
Conditions
tinnitus
Beyond the preview
Go deeper on 2013-005588-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005588-24.